PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Chlorzoxazone→

Chlorzoxazone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
95-25-0
Molecular formula
C7H4ClNO2
Molecular weight
169.565 g/mol
Drug class
Centrally acting skeletal-muscle relaxant
Mechanism of action
The mechanism of action is not fully established. It is thought to act primarily at spinal and subcortical levels to inhibit polysynaptic reflex arcs involved in skeletal-muscle spasm; it does not directly relax skeletal muscle or act at the neuromuscular junction.
Indications / reported uses
  • Adjunct to rest, physical therapy and other measures for short-term relief of discomfort associated with acute painful musculoskeletal conditions in adults

Sources: US DailyMed — Chlorzoxazone tablets · NLM MeSH — Chlorzoxazone · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Chlorzoxazone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Chlorzoxazone Permitted Daily Exposure (PDE) report (the Chlorzoxazone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Chlorzoxazone Occupational Exposure Limit (OEL) report (the Chlorzoxazone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.